Medical Oncology

, Volume 21, Issue 2, pp 205–206 | Cite as

Rituximab-induced tumor progression

Does it really happen?
  • Mustafa Ozguroglu
  • Hande Turna


Chronic Lymphocytic Leukemia Hairy Cell Leukaemia Medical Oncology Volume Accelerate Progression Rituxan 


  1. 1.
    Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol 2002;29(1 Suppl 2):105–112.PubMedCrossRefGoogle Scholar
  2. 2.
    Czuczman MS, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002;29(1 Suppl 2):36–40.PubMedCrossRefGoogle Scholar
  3. 3.
    Al-Salman J, Salib H, Boonswang P. Successful treatment of gastrointestinal follicular lymphoma with rituxan and combination chemotherapy. Med Oncol 2001;18(4):277–283.PubMedCrossRefGoogle Scholar
  4. 4.
    Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 2001;115(3):609–611.PubMedCrossRefGoogle Scholar
  5. 5.
    Chemnitz J, Draube A, Diehl V, Wolf J. Successful treatment of steroid and cyclophosphamide-resistant hemolysis in chronic lymphocytic leukemia with rituximab. Am J Hematol 2002;69(3):232–233.PubMedCrossRefGoogle Scholar
  6. 6.
    Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002;116(2):465–467.PubMedGoogle Scholar
  7. 7.
    Zaja F, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002;87(2):189–195.PubMedGoogle Scholar
  8. 8.
    Treon SP, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002;25(1):72–81.PubMedCrossRefGoogle Scholar
  9. 9.
    Coiffier B, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl Med J Med 2002;346:235–242.CrossRefGoogle Scholar
  10. 10.
    Coiffier B. Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol 2002;29(1 Suppl 2):30–35.PubMedCrossRefGoogle Scholar
  11. 11.
    Korte W, Jost C, Cogliatti S, Hess U, Cerny T. Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy. Ann Oncol 1999;10(10):1249–1250.PubMedCrossRefGoogle Scholar
  12. 12.
    Bellosillo B, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001;98(9):2771–2777.PubMedCrossRefGoogle Scholar
  13. 13.
    van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115(4):807–811.PubMedCrossRefGoogle Scholar
  14. 14.
    Cardarelli PM, et al. Binding to CD20 by Anti-B1 Antibody or F(ab’)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002;51(1):15–24.PubMedCrossRefGoogle Scholar
  15. 15.
    Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29(1 Suppl 2):2–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Chow KU, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002;87(1):33–43.PubMedGoogle Scholar
  17. 17.
    Bienvenu J, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2001;2(6):378–384.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2004

Authors and Affiliations

  • Mustafa Ozguroglu
    • 1
  • Hande Turna
    • 1
  1. 1.Cerrahpasa Medical Faculty, Department of Internal Medicine, Section of Medical Oncology, CerrahpasaIstanbul UniversityIstanbulTurkey

Personalised recommendations